Core Insights - Twist Bioscience reported a strong first-quarter performance for fiscal 2026, with revenue reaching $103.7 million, reflecting a 17% year-over-year growth and marking the 12th consecutive quarter of revenue growth [5][4]. - The growth was significantly driven by demand for AI-enabled discovery, with over $25 million in orders specifically tied to this area booked for fiscal 2025 [1][5]. - The company aims for adjusted EBITDA break-even by the fourth quarter of fiscal 2026, while also increasing operating expenses to support growth [13][5]. Financial Performance - DNA synthesis and protein solutions (DSPS) revenue increased to $51.1 million, up 27% year-over-year [1]. - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million compared to the prior-year quarter [3]. - Gross margin was reported at 52.0%, higher than expected, attributed to revenue growth and process improvements [4]. Market Trends - The company is expanding its services beyond DNA synthesis to include protein expression and antibody characterization, targeting large pharma, tech companies, and well-funded biotechs [6]. - NGS applications revenue was approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [7]. - Therapeutics revenue increased to approximately $37.2 million, up 39% year-over-year, driven by greater uptake from large pharma and biotech [15]. Guidance and Outlook - Twist raised its full-year revenue outlook to $435 million to $440 million, indicating about 16% growth at the midpoint [12]. - For the second quarter, the company expects revenue of $107 million to $108 million, also reflecting about 16% growth at the midpoint [12]. - Management expressed confidence in continued growth in NGS driven by key accounts and partnerships [9][10]. Geographic and Sector Performance - Revenue by geography showed growth in the Americas ($58.4 million), EMEA ($38.4 million), and APAC ($7.0 million) compared to the previous year [11]. - Global supply partner revenue rose to $12.8 million, a 50% increase, attributed to new partnerships and growth among diagnostics OEM partners [11]. - Academic research and government revenue remained flat at approximately $12.2 million, with expectations for growth in the second quarter due to increased confidence in NIH funding [15].